Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E B Silberstein

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|March 31, 2001
Positron-emitting radiopharmaceuticals: how safe are they?E B Silberstein
The New England Journal of Medicine|July 18, 1974
Letter: Extension of two-part consent formE B Silberstein
JAMA|March 22, 1971
Anemia of chronic renal failureE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1974
Letter: Calcium, phosphorus, 99mTc "uptake"E B Silberstein
British Medical Journal|August 22, 1970
Myasthenia gravis, haemolytic anaemia, and lymphoreticular malignancyE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 1998
Drug labeling changesE B Silberstein
Seminars in Oncology|June 1, 1993
The treatment of painful osseous metastases with phosphorus-32-labeled phosphatesE B Silberstein
Chest|January 1, 1987
Lung scintigraphyE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 1976
Causes of abnormalities reported in nuclear medicine testingE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 1998
Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear MedicineE B Silberstein
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
Cancer Biotherapy & Radiopharmaceuticals|March 31, 2001
Positron-emitting radiopharmaceuticals: how safe are they?E B Silberstein
The New England Journal of Medicine|July 18, 1974
Letter: Extension of two-part consent formE B Silberstein
JAMA|March 22, 1971
Anemia of chronic renal failureE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1974
Letter: Calcium, phosphorus, 99mTc "uptake"E B Silberstein
British Medical Journal|August 22, 1970
Myasthenia gravis, haemolytic anaemia, and lymphoreticular malignancyE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 17, 1998
Drug labeling changesE B Silberstein
Seminars in Oncology|June 1, 1993
The treatment of painful osseous metastases with phosphorus-32-labeled phosphatesE B Silberstein
Chest|January 1, 1987
Lung scintigraphyE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 1976
Causes of abnormalities reported in nuclear medicine testingE B Silberstein
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 29, 1998
Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear MedicineE B Silberstein
Pageof 13